Nascent Biotech Inc
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing Multi… Read more
Nascent Biotech Inc (NBIO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: 0.631x
Based on the latest financial reports, Nascent Biotech Inc (NBIO) has a cash flow conversion efficiency ratio of 0.631x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-324.73K) by net assets ($-514.54K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nascent Biotech Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Nascent Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Nascent Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nascent Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Financial 15 Split Corp
PINK:FNNCF
|
-0.011x |
|
Boratr Co. Ltd.
KO:250000
|
0.013x |
|
Feel Foods Ltd
PINK:FLLLF
|
0.007x |
|
ALUP11F
SA:ALUP11F
|
N/A |
|
VERASTEM (2VS.SG)
STU:2VS
|
-0.689x |
|
Big Tech 50 R&D-Limited Partnership
TA:BIGT
|
-0.008x |
|
Misr Beni Suef Cement
EGX:MBSC
|
N/A |
|
Arogo Capital Acquisition Corp. Warrant
NASDAQ:AOGOW
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Nascent Biotech Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of Nascent Biotech Inc from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-03-31 | $-256.67K | $-1.19 Million | 4.621x | +235.12% |
| 2023-03-31 | $-1.30 Million | $-1.79 Million | 1.379x | +323.93% |
| 2022-03-31 | $-671.48K | $413.48K | -0.616x | -129.49% |
| 2021-03-31 | $-472.50K | $-986.78K | 2.088x | +983.42% |
| 2020-03-31 | $-2.88 Million | $-554.33K | 0.193x | -86.94% |
| 2019-03-31 | $-482.16K | $-711.81K | 1.476x | -89.58% |
| 2018-03-31 | $-86.38K | $-1.22 Million | 14.175x | +1452.77% |
| 2017-03-31 | $733.76K | $-768.84K | -1.048x | -1064.54% |
| 2016-03-31 | $-1.57 Million | $-170.42K | 0.109x | -49.34% |
| 2015-03-31 | $-2.21 Million | $-473.30K | 0.214x | +140.10% |
| 2014-03-31 | $-1.45 Million | $-129.53K | 0.089x | -- |